Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03793478 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood
A Phase 1 study of Acute Myeloid Leukemia, sponsored by Daiichi Sankyo.
- Active
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
- 20
- Study locations
NCT03793478: Active Phase 1 study of Acute Myeloid Leukemia, sponsored by Daiichi Sankyo.
NCT03793478 is a Phase 1 study of Acute Myeloid Leukemia that is active but no longer recruiting, run by Daiichi Sankyo. The registered enrollment target is 65 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (44% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03793478, a Phase 1 study of Acute Myeloid Leukemia, is active but no longer recruiting, sponsored by Daiichi Sankyo.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
- 20
- Study locations
Study Summary
Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research. Children or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or is not responding to treatment.
Conditions Studied
Interventions
- DRUG Fludarabine
- DRUG Etoposide
- DRUG Cytarabine
- DRUG Quizartinib
- DRUG Intrathecal (IT) triple chemotherapy prophylaxis
Study Locations (20)
Other
- Universitair Ziekenhuis Gent - Ghent
- British Columbia Children's Hospital - Vancouver
- Rigshospitalet - Copenhagen
- Centre Léon Bérard - Lyon
- Hôpital Armand-Trousseau - Paris
- Hôpital des Enfants - Toulouse
- Rambam Medical Center - Haifa
- Tel Aviv Sourasky Medical Center - Tel Aviv
California
- Loma Linda University Cancer Center - Loma Linda
- University of California, San Francisco - San Francisco
Colorado
- Children's Hospital Colorado - Aurora
Delaware
- A.I. duPont Hospital for Children - Wilmington
District of Columbia
- Children's National Medical Center - Washington D.C.
Georgia
- Children's Healthcare of Atlanta - Atlanta
Minnesota
- University of Minnesota/Masonic Cancer Center - Minneapolis
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2018-08-15 |
| Est. Completion | 2027-05-01 |
| Phase | Phase 1 |
What the registry record for NCT03793478 still lists
NCT03793478 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (44% lower).
The record links to 1 condition, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Fludarabine is the first listed.
NCT03793478 names 20 study sites across 12 states, led by Other, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT03793478 about?
NCT03793478 is a clinical study titled "Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood". Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research. Children or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or is not responding to treatment.
What is the current status of trial NCT03793478?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2018-08-15. Estimated completion is 2027-05-01.
What conditions does trial NCT03793478 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia.
What interventions are being tested in trial NCT03793478?
The interventions under investigation include: Fludarabine (DRUG), Etoposide (DRUG), Cytarabine (DRUG), Quizartinib (DRUG), Intrathecal (IT) triple chemotherapy prophylaxis (DRUG).
Who is sponsoring clinical trial NCT03793478?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03793478 being conducted?
This trial has 20 study locations across California, Colorado, Delaware, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03793478's enrollment target sits among peer trials
65 114th of 306 higher than 193 of 306 other Acute Myeloid Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
RECRUITING · Phase 1
-
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
RECRUITING · Phase 1
-
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
RECRUITING · Phase 1
-
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI